TD2 to Highlight Development of a Dual-Specific Inhibitor for Treatment of Primary Myelofibrosis at ASH Annual Meeting

December 05, 2023

SCOTTSDALE, ARIZONA, USA, December 5, 2023 /EINPresswire.com/ Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of preclinical results of RR-1752, a targeted inhibitor of ROCK/AURK, for primary myelofibrosis at the American Society of Hematology (ASH) Annual Meeting in San Diego, CA, to be held December 9-12, 2023.

The poster will be presented by lead Author Liqiang Zhang, PhD, Senior Scientist at TD2 and will discuss the promising preclinical results assessing efficacy and the safety profile of RR-1752 in animal models.

“TD2 is proud to unveil our innovative research in the development of RR-1752, a dual-specific inhibitor of ROCK and AURK, for the treatment of primary myelofibrosis (PMF). PMF is a complex hematological disorder that profoundly affects patients’ lives through bone marrow fibrosis and debilitating symptoms,” said Dr. Alan Miller, Chief Medical Officer at TD2. “Our study represents a significant step forward in the preclinical development of RR-1752 demonstrating tolerability and improved survival in a tumor model of human myelofibrosis. The data demonstrate RR-1752 significantly extends survival with minimal toxicity compared to the approved JAK2 inhibitor ruxolitinib. This achievement underscores our dedication to advancing novel agents for patients with primary myelofibrosis with disease modifying potential.”

TD2’s team of experts will be available throughout the conference to engage in discussions, share insights, and address inquiries related to their research.

The ASH Annual Meeting serves as a premier platform for hematology professionals worldwide to convene, exchange knowledge, and unveil the latest breakthroughs in the treatment of hematological diseases. TD2’s participation underscores its commitment to advancing research, developing novel therapeutic options, and enhancing the lives of individuals afflicted with hematological disorders.

Abstract 4592: A Dual-Specific Inhibitor of ROCK/AURK, RR-1752, for Primary Myelofibrosis (Monday, December 11 6:00-8:00 PM PST) within Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational, Poster Session 631
Authors: L. Zhang(1), K. McGinnis (1), P. Gonzales (1), M. Murray (1), E. Cluff (1), MD B. Mia (2), C. Schaniel (2), J. Mascarenhas (1), A. M. Miller (1), R. Hoffman(2), and S. Gately (1)
1) Translational Drug Development (TD2), Scottsdale, AZ
2) The Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine At Mount Sinai, New York, NY

Top Trends in ADC Drug Development

Antibody drug conjugates (ADCs) represent a significant advancement in cancer therapy, combining monoclonal antibodies with potent chemotherapeutic ...

Read more +

Unlocking Insights: Top 5 Reasons to Incorporate Orthotopic GBM PDX Models into Your Preclinical Evaluation

In the landscape of glioblastoma multiforme (GBM) research, the utilization of Orthotopic GBM Patient-Derived Xenograft (PDX) models stands as a ...

Read more +

The Vital Role of Highly Characterized Glioblastoma PDX Models in Preclinical Cancer Research: Insights from TD2's Most Recent Studies

The fight against Glioblastoma multiforme (GBM), one of the most aggressive forms of brain cancer, hinges on the development and use of advanced ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.